Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering AbbVie (ABBV) , which belongs to the Zacks Large Cap Pharmaceuticals industry.This drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 2.93%.For the last reported quarter, AbbVie came out with earnings of $3 per share versus ...

Get Treated with CoolSculpting® Elite and Enter for a Chance to Win $10,000* Starting Today, First-Time Users Can Claim $300 Off Their Treatment† IRVINE, Calif., Jan. 7, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an opportunity for consumers interested in body contouring to reach out to a CoolSculpting® Elite expert and discuss their body contouring treatment options. CoolSculpting® is the ...

In an SEC filing, AbbVie (ABBV) has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per share (EPS) by 88 cents due to in-process research and development (IPR&D) expenses incurred for acquisitions and collaborations during the fourth quarter.The adjusted EPS guidance for full-year 2024 was lowered from $10.90-$10.94 to $10.02-$10.06 due to acquisition costs of $1.6 billion on a pre-tax basis. The Zacks Consensus Estimate for this metric is pegged at $10.96.Including ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 ABBVIE INC. (Exact name of registrant as specified in its charter) (State or other Jurisdiction (Commission File Number) (IRS Employer Delaware 001-35565 32-0375147 of Incorporation) Identification No.) 1 North Waukegan Road ...

When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising their payouts at a rapid pace, but these stocks tend to offer low yields. The other basic option available to dividend investors is to buy stocks with really high yields. Unfortunately, stocks rarely offer ultrahigh yields unless there's concern about their ability to raise or maintain their dividend payouts.If you can't decide which dividend investing option you like best, I have some ...

If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constant concern for most families.There isn't much that you can do to stop the march of inflation, but you can prepare. Filling your portfolio with dividend-paying stocks that raise their quarterly payouts faster than the underlying inflation rate could even lead to extra spending cash.Medtronic (MDT 0.91%), Bristol ...

NORTH CHICAGO, Ill., Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative me ...

Industry Overview - The drug and biotech industry faced challenges in the past months due to disappointing Q3 sales, guidance cuts, and pipeline setbacks, but is expected to recover in 2025 [2] - Innovation in areas like rare diseases, oncology, obesity, immunology, and neuroscience is driving investor interest, with R&D remaining a key focus in 2025 [3] - The Zacks Large Cap Pharmaceuticals industry includes global companies developing drugs for therapeutic areas like neuroscience, cardiovascular, rare diseases, immunology, and oncology, with some also involved in vaccines, animal health, and medical devices [5] - Large drugmakers invest heavily in product pipelines and line extensions, with continuous innovation and M&A activity being defining characteristics [6] Key Drivers and Challenges - Innovation and pipeline success are critical for top-line growth, with pharma companies spending a significant portion of revenues on R&D [7] - Aggressive M&A activity is a key feature, with large companies acquiring smaller biotech firms to build pipelines, particularly in oncology, rare diseases, and cell and gene therapy [8][9] - Recent major M&A deals include Eli Lilly's buyout of Morphic, Vertex's acquisition of Alpine Immune Sciences, and Novo Nordisk's purchase of Catalent [10] - Pipeline setbacks, regulatory delays, pricing pressure, generic competition, and macroeconomic uncertainty are significant headwinds for the industry [11][12] Industry Performance and Valuation - The Zacks Large Cap Pharmaceuticals industry has a Zacks Industry Rank of 146, placing it in the bottom 41% of Zacks industries [14] - The industry has outperformed the Zacks Medical Sector but underperformed the S&P 500, with a 1.2% decline over the past year compared to the S&P 500's 26.2% rise [15] - The industry's forward 12-month P/E ratio is 18.64X, lower than the S&P 500's 25.08X and the Zacks Medical Sector's 25.47X [16] Key Companies to Watch - **J&J**: Diversified business model with strong growth in the Innovative Medicines segment, expected to exceed $57 billion in sales in 2025 [17][18] - **Pfizer**: Strengthened oncology position with Seagen acquisition, expects operational growth driven by new products and cost cuts of at least $5.5 billion [21][22][23] - **AbbVie**: Successfully navigating Humira's loss of exclusivity with new immunology drugs Skyrizi and Rinvoq, expects mid-single-digit revenue growth in 2025 [24][25][26] - **Eli Lilly**: Strong performance from tirzepatide medicines Mounjaro and Zepbound, with demand expected to drive revenue growth in 2025 [28][29][30][31] - **AstraZeneca**: Diversified portfolio with 12 blockbuster drugs, expects industry-leading top-line growth and $80 billion in revenues by 2030 [33][34][35]

One of the highest achievements a dividend growth stock can attain is the status of a Dividend King. To reach this milestone, a company must increase its annual dividend payout for 50 consecutive years. That is not an easy feat toI have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting. I have worked in the investment arena for over 10 years starting as an analyst and working my way up to a management role. Dividend investing is a personal hobby and I look forwa ...

PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in various breast cancer treatment scenarios. Predominantly utilized before and after surgery, these drugs are pivotal in managing the disease. Significant research efforts are focused on targeted therapies tailored to specific breast cancer types, particularly those characterized by overexpression of human epidermal grow ...